In this issue, Schlessinger and his colleagues (Yuzawa et al., 2007) describe crystal structures of the complete extracellular region of the Kit receptor tyrosine kinase, both alone and in complex with its activating ligand, stem cell factor (SCF). The structures explain how SCF drives dimerization of the receptor. They also reveal important receptor-receptor contacts that may explain how several Kit mutations lead to cancer.
Mitochondria are ubiquitous organelles found in all nucleated cells and are the primary generators of cellular ATP by oxidative phosphorylation (OXPHOS). OXPHOS depends upon the coordinated expression, interaction, and regulation of both nuclear genes and the mitochondrial genome (mtDNA). The latter is a 16.6 kb circular DNA molecule that encodes 13 essential polypeptides of the OXPHOS system and the necessary RNA machinery (2 rRNAs and 22 tRNAs) for the translation of mtDNA transcripts. mtDNA has two strands, a guanine-rich heavy strand and a cytosine-rich light strand. Transcription from the heavy strand generates all 13 mRNAs with the exception of ND6 (Figure 1 ). The mitochondrial genome is remarkably compact in terms of the organization of its genetic material, with the only major region of noncoding sequence, the 1.1 kb control region, containing important regulatory elements for mtDNA expression (AsinCayuela and Gustafsson, 2007) . In this issue, Park et al. (2007) identify a nuclear encoded protein, MTERF3, as the first negative regulator of mitochondrial DNA transcription.
Much of our understanding of the basic principles of mitochondrial genetics, inheritance, and gene expression has arisen from the study of disease pathology. Patients with mitochondrial diseases, specifically respiratory chain disorders, harbor either sporadic or maternally transmitted mtDNA mutations, or mutations in nuclear genes involved in either mtDNA maintenance-such as the mtDNA polymerase γ (POLG1) gene-or respiratory chain complex assembly. These give rise to a spectrum of multisystem disorders that affect both children and adults. They commonly involve muscle and the central nervous system but can present with varying degrees of organ severity and specificity (Taylor and Turnbull, 2005) . Moreover, mtDNA mutations have been implicated in the aging process (Kirkwood, 2005) ; high levels of somatic mtDNA mutations have been identified in cells with an OXPHOS deficiency in both aging and neurodegenerative disorders (Bender et al., 2006) , although their precise role continues to provoke much debate (Khrapko and Vijg, 2007) .
In this issue of Cell, Park et al. (2007) describe the nuclear encoded protein MTERF3 as a negative regulator of mitochondrial DNA transcription initiation. This study highlights a mechanism by which mitochondrial DNA transcription (and therefore oxidative phosphorylation) may be regulated in response to alterations in the cell's physiological and metabolic demands. Shown is a map of the 16.6 kb circular, double-stranded mitochondrial genome encoding 13 proteins, 22 tRNAs, and 2 rRNAs. The 1.1 kb noncoding control region is shown in linear form. Transcription of the heavy strand is initiated either from the heavy-strand promoter 1 (HSP1), generating a short transcript that terminates at the 16S rRNA, or from HSP2, generating a polycistronic message including both rRNA genes, 12 mRNA genes, and 14 tRNA genes. Light-strand transcription from the light-strand promoter (LSP) generates the ND6 mRNA and 8 tRNAs. Transcription from all promoters requires the involvement of the transcriptional activator TFAM that binds upstream of the promoters, together with a single subunit RNA polymerase (POLRMT), which forms a heterodimeric complex with one of two transcription factors, TFB1M or TFB2M. Together with as yet unidentified interacting partners that are crucial for its function, MTERF3 acts as a negative regulator of transcription by binding to mitochondrial DNA at or near the light-strand promoter and heavy-strand promoters.
The principal mitochondrial transcription machinery has been elucidated and comprises a mitochondrial RNA polymerase (POLRMT), a mitochondrial transcription factor A (TFAM), and one of two homologous mitochondrial transcription factors, B1 (TFB1M) or B2 (TFB2M) (Falkenberg et al., 2002) . In spite of considerable knowledge concerning the machinery involved, the regulation of mitochondrial transcription, its coupling to protein translation, and ribosome biogenesis are poorly defined, although new regulatory proteins continue to be identified (Wang et al., 2007) . An understanding of these processes is crucial not only for establishing the regulatory mechanisms and how these mechanisms fine tune mitochondrial function but also for elucidating the basis of mitochondrial disease. Given the recent finding of mutations in nuclear genes encoding ribosomal proteins and elongation factors leading to generalized defects in translation (Coenen et al., 2004) , it is not unreasonable to speculate that human mitochondrial transcription defects may also represent an as yet undefined but important class of OXPHOS disorders.
The mitochondrial transcription termination factors are a group of DNAbinding proteins including MTERF (also called MTERF1) that are thought to be involved in the regulation of mitochondrial transcription, although their functions and mechanism of action remain to be defined. Evidence for a new player in this process is provided in this issue of Cell by Larsson, Gustafsson, and their colleagues (Park et al., 2007) , who identify MTERF3, a previously uncharacterized mitochondrial protein, as a transcriptional repressor through its binding to the mtDNA promoter region (Figure 1) . Originally identified by PSI-BLAST searches of the NCBI protein sequence database, MTERF3 is ubiquitously expressed and shown by the authors to be targeted to mitochondria. Confirmation of MTERF3's role in cell viability and maintaining OXPHOS capacity is provided by elegant studies in mice lacking MTERF3. Homozygous Mterf3 knockout mouse embryos die at around embryonic day (E)8.5; embryonic lethality was rescued by the reintroduction of the Mterf3 gene. Tissue-specific knockout of MTERF3 in the heart revealed several features consistent with marked mitochondrial respiratory chain dysfunction. These mice had a shortened life span and enlarged hearts with increased numbers of abnormal mitochondria as detected by electron microscopy. These defects were associated with a progressive loss of MTERF3 protein and a marked reduction in the levels of assembled respiratory chain complexes containing mtDNA-encoded subunits. Direct enzyme measurements confirmed multiple respiratory chain deficiencies and increased citrate synthase activity in agreement with the electron microscopy findings.
Hearts lacking MTERF3 had normal mtDNA levels and, surprisingly, exhibited increased steady-state levels of RNA19 (a well-defined transcript precursor encompassing 16S rRNA and ND1, which is known to accumulate in patients with mt-tRNA Leu(UUR) mutations) and of some tRNAs (transcribed from either the light-strand promoter or the heavy-strand promoter). Interestingly, steady-state levels of tRNAs close to the light-strand promoter or the heavy-strand promoter were increased, whereas tRNAs distal to the promoters showed decreased steady-state levels. In addition, chromatin immunoprecipitation analyses with MTERF3 antibodies showed binding to mtDNA at or near the lightstrand promoter or the heavy-strand promoter, implying that MTERF3 might affect transcription initiation. Direct assays subsequently revealed that mtDNA transcription initiation indeed was increased from both promoters in mitochondria lacking MTERF3. Finally, to verify a role for MTERF3 in transcription repression, the authors measured de novo mtDNA transcription in mitochondrial extracts before and after MTERF3 immunodepletion. Addition of exogenous MTERF3 could not rescue transcriptional activity, suggesting that MTERF3 depletion leads to loss of other interacting factors required for its function.
These observations raise some fascinating insights into the role of MTERF3, not the least of which is the potential mechanism by which the MTERF3 knockout mice develop respiratory chain dysfunction in heart tissue. It is surprising that heart muscle cells that lack MTERF3 have enhanced mitochondrial transcription yet exhibit such a severe biochemical defect. The authors present data suggesting that decreased levels of certain tRNAs cause the respiratory chain deficiency. However, we propose an alternate possibility, namely that it is the proportion of transcripts and not their abundance per se that plays a role in regulating mitochondrial translational activity. In this regard, an additional but as yet undetermined role for MTERF3 may be important. Both TFB1M and TFB2M transcription factors have strong sequence homology with bacterial rRNA methyltransferases, which has led some to speculate that these proteins may possess a bifunctional role, namely the recognition of specific DNA sequences to facilitate promoter recognition by the single subunit RNA polymerase POLRMT (Falkenberg et al., 2002) . Increased levels of RNA19 in MTERF3-deficient organelles suggest that MTERF3 may be important in RNA processing; and data from Drosophila indicate its possible role in controlling mitochondrial translation in flies (Roberti et al., 2006) .
The identification of MTERF3 represents a major step in defining the precise molecular machinery in mammals that controls mitochondrial transcription in vivo, with studies in mice highlighting a new disease mechanism that leads to mitochondrial respiratory chain deficiency. Ongoing studies will be of great importance in providing not only a greater understanding of basic mitochondrial physiology but also insights into possible therapeutic interventions for treating disorders associated with mitochondrial DNA-mediated respiratory chain dysfunction.
